Old Web
English
Sign In
Acemap
>
Paper
>
Comment On: “EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars”
Comment On: “EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars”
2014
John Joseph Borg
Anthony Serracino-Inglott
Lilian M. Azzopardi
Christian K. Schneider
Keywords:
Biosimilar Pharmaceuticals
Biosimilar
Pharmacology
Alternative medicine
Medicine
Pharmacovigilance
Legislation
reference product
pharmacology toxicology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
2
References
1
Citations
NaN
KQI
[]